Long-term growth hormone therapy in mitochondrial cytopathy

Salvatore Barberi, Elena Bozzola, Angela Berardinelli, Cristina Meazza, Mauro Bozzola

Research output: Contribution to journalArticlepeer-review


Objective: To describe in a 5-year-old Caucasian male with mitochondrial cytopathy, a biochemical growth hormone (GH) deficiency associated with normal GH biological activity as evaluated by Nb2 cell bioassay and normal serum IGF-I and IGFBP3 values increasing slightly after GH administration. Method: Serum GH concentrations were measured with a commercial immunofluorometric assay and with a biological assay, which uses the Nb2 cell line. Serum IGF-I and IGFBP3 concentrations were measured with RIA. Results: The GH-supplementary therapy was initially effective in terms of growth gain, but no therapeutic benefit was observed over a long period of time. Conclusion: In patients suffering from mitochondrial cytopathy, short stature seems to be attributed more to a disease-related inadequate protein substrate than to the non-classical GH deficiency.

Original languageEnglish
Pages (from-to)103-106
Number of pages4
JournalHormone Research
Issue number2
Publication statusPublished - 2004


  • Growth hormone deficiency
  • Growth hormone therapy
  • Mitochondrial cytopathy

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Long-term growth hormone therapy in mitochondrial cytopathy'. Together they form a unique fingerprint.

Cite this